

disease although any specific amount has not been established. This study aimed to analyze the amount and type of dietetic fat and carbohydrates related with hepatic steatosis in a group of Mexican adults in a typical diet.

Materials and Methods: In a group of Mexican adults without hepatic steatosis, a registered cross-sectional study INCMNSZ- 3794-21/22 consuming a typical diet, were applied food frequency questionnaires, anthropometry and transient elastography. If they had any chronic disease, uncontrolled diabetes, hypertension or thyroid disease, bariatric surgery or pacemaker, were not included. Dietary fat and carbohydrates were identified and quantified with The Food Processor software v11.11.32 (ESHA Co.); manually, the proportion of fats was classified according to WHO recommendations. Differences among steatosis group (CAP > 268 dB/m) were calculated with t-Student and a logistic regression to determine odds ratio with type and amount of nutrients related to hepatic steatosis.

Results: Of 321 participants, 200 were women; 162 had steatosis and were older, with higher BMI, waist circumference, fat mass and visceral fat ($p=0.000$); they also consumed more carbohydrates, total sugar and added sugars (113.8 g, 98.1 g and 52.6 g, respectively) compared to non-steatosis group ($p=0.000$). There were no statistical differences in total either type of fats. For carbohydrates were obtained OR= 2.44 (IC95% 1.4- 4.62, $p=0.002$), total sugar OR= 2.67 (IC95% 1.48- 4.63, $p=0.001$) and added sugars OR= 2.68 (IC95% 1.49- 4.83, $p=0.001$).

Conclusions: Unlike fats, type and amounts of dietary sugars are relevant risk factors for hepatic steatosis in a typical Mexican diet. In this study, we identified the amount that could be related to damage for non-alcoholic fatty liver disease.

<https://doi.org/10.1016/j.aohep.2023.101233>

P- 47 ACCURACY OF MAFLD-S SCORE TO DIAGNOSE HEPATIC STEATOSIS IN A GROUP OF APPARENTLY HEALTHY PEOPLE.

Luis Carlos Chávez¹, Juan Adrián Torres¹,
Sophía Eugenia Martínez¹, Ashuin Kammar²,
Antonio Olivas³, Jesús Alejandro Ruiz¹,
Luis Federico Uscanga¹, Graciela Castro¹

¹ Gastrointestinal Endoscopy Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, México

² Research Division, National Institute of Geriatrics, Mexico City, México

³ Biostatistics Department, University of Washington, Washington, Estados Unidos (EEUU)

Introduction and Objectives: Non-invasive methods for diagnosing metabolic associated fatty liver disease (MAFLD), like Fatty Liver Index (FLI) are gaining attention due to their potential to diagnose patients and reduce healthcare costs. A recent development in non-invasive diagnostics is the MAFLD-S score, which utilizes clinical data exclusively to predict MAFLD risk. This study aimed to evaluate the accuracy of MAFLD-S to diagnose hepatic steatosis previously identified by transient elastography.

Materials and Methods: A cross-sectional study was conducted. Transient elastography with controlled attenuation parameter (CAP) threshold of >268 dB/m was performed to measure hepatic steatosis (HS). Medical histories and anthropometric measurements were collected, and both the MAFLD-S score and FLI were calculated for each participant using cut-off points of 0.548 and 60, respectively. Statistical analysis, including Spearman's correlation and receiver operating characteristic (ROC) curve analysis, was performed to evaluate the diagnostic of HS.

Results: The study included 513 participants, with 64% being females and a mean age of 41.4 years. Hepatic steatosis was diagnosed in 46% of the population using transient elastography. Significant correlations were observed between the MAFLD-S score and FLI ($s=0.726$, $p=0.000$) The MAFLD-S score demonstrated a sensitivity (Se) of 63% and specificity (Sp) of 80% for detecting hepatic steatosis, and an area under the curve (AUC) of 0.795; the predictive positive value (PPV) was 0.728 and the positive likelihood ratio (+LR) was 3.15. FLI demonstrated Se= 58%, Sp= 81%, AUC= 0.818, PPV= 0.726 and +LR= 3.11.

Conclusions: In a group of apparently healthy people, both MAFLD-S score and FLI exhibited significant performance to diagnose hepatic steatosis. Implementing this clinical score can aid in identifying individuals at prompt early intervention to improve patient outcomes. Additional research is required to assess the diagnostic performance of these scores in patients with MAFLD.




Figure 1. Performance of MAFLD-S and FLI scores for the diagnosis of hepatic steatosis compared to CAP.

<https://doi.org/10.1016/j.aohep.2023.101234>

P- 48 EFFECT OF THE COMBINATION OF ORLISTAT AND L-CARNITINE ON THE QUALITY OF LIFE (SF.36) IN 16 OVERWEIGHT PATIENTS

Miguel Yael Carmona¹, Saúl André Vera¹,
María De Fatima Higuera¹, Livan Delgado²,
Santiago Camacho¹

¹ Gastroenterología, Hospital General de México, Ciudad de México, México


² Gerente de Investigación Clínica, Laboratorios Liomont, Ciudad de México, México

Introduction and Objectives: Orlistat is a drug widely used in overweight/obese patients, while the combination with l-carnitine could offer an improvement in these patients. To our knowledge, the effect of this combination on the quality of life of overweight patients has not been determined. We aimed to evaluate the effects on the quality of life of patients who took the combination of orlistat and l-carnitine at 4 and 8 weeks of treatment.

Materials and Methods: We evaluated the quality of life (Short Form-36) in 16 patients [41.81±8.26 (37.77-45.86) years, 81% women] undergoing pharmacotherapy of the combination of orlistat and l-carnitine at 4 and 8 weeks of treatment. Data express mean SD and 95%IC or percentages as correspond. We use paired Student t Test, two tails with an alpha=0.05.

Results: Figure. Patients lowered their weight in about 5%. Patients show improvement on body pain, general health, vitality and in both Mental [45.68±6.51 (42.49-48.86) vs. 49.88±3.21 (48.31-51.46), $p=0.02$] and Physical [59.4±8.92 (55.03-63.77) vs. 63.36±9.64 (58.63-68.08), $p=0.01$] summaries.

Conclusions: These results suggest a beneficial effect of the combination of Orlistat and L-carnitine on the treatment of overweight.



<https://doi.org/10.1016/j.aohep.2023.101235>

P- 49 DECOMPETATIONS CAUSING ADMISSION, READMISSION AND MORTALITY IN CIRRHOTIC PATIENTS ADMITTED AT EUGENIO ESPEJO SPECIALTY HOSPITAL. QUITO, ECUADOR

Walkenys Abigail Waldroph, Wilson Enrique Carrera

Gastroenterology Section. Eugenio Espejo Specialty Hospital. Quito, Ecuador

Introduction and Objectives: Liver cirrhosis is the seventh cause of death in Ecuador and highest morbidity and mortality is a consequence of the decompensation of the disease. This study aimed to analyze the decompensations that cause admission, readmission and mortality in cirrhotic patients admitted to the gastroenterology unit at Eugenio Espejo Specialty Hospital from January 2020 to December 2021

Materials and Methods: a descriptive, observational and cross-sectional view study was conducted, with non-probabilistic random convenience sampling. We obtained the data from the medical records using the data collection instrument developed for this purpose and the data were analyzed using the statistical package IBM SPSS Statistics v28.

Results: 251 admissions for decompensated cirrhosis were analyzed, corresponding to 147 patients, of which 65.31% registered only one admission and 34.69% readmitted at least once during the study period. In the sample, 51.7% were women, and mean age was 62.08 (+/-12.8) years. The main etiology of cirrhosis was cryptogenic in females and enolic in males. The main cause for admission in the first hospitalization was upper gastrointestinal bleeding, reported in 37.4%, followed by encephalopathy and ascites (32.0% and 23.8%). The 30 and 90-days readmission rates were 41.3% and 32.7%, respectively, and the main cause for readmission was encephalopathy in 50% of patients, followed by upper gastrointestinal bleeding in 47.1% (mostly non-variceal). In-hospital mortality was 8.4% and the main associated complications were encephalopathy and acute kidney injury, both described in 47.6% of patients.

Conclusions: the main complication that led to hospital admission in the first hospitalization was variceal upper gastrointestinal bleeding and encephalopathy on readmission. The complications associated with higher mortality were encephalopathy, acute kidney injury and ACLF.

<https://doi.org/10.1016/j.aohep.2023.101236>

P- 50 VALIDATION OF S-ANT FOR THE DIAGNOSIS OF HEPATIC ENCEPHALOPATHY MINIMUM

Jose Luis Perez, Irais Alejandra Garcia, Maria De Fatima Higuera, Daniel Santana, Silvia Johanna Lozada, Leonardo Samuel Juarez, Diana Montemira, Christian Israel Hinojosa


Hospital General De México Dr. Eduardo Liceaga, Ciudad de México, México

Introduction and Objectives: Hepatic encephalopathy (HE) is one of the most frequent complications of cirrhosis. Minimal hepatic encephalopathy (MHE) is the initial stage and is characterized by the fact that it has no clinical data; its diagnosis is made with neuropsychological tests, the MHE produces a deterioration in the quality of life of patients and an increased risk of accidents. Hence, it is relevant to diagnose. Performing neuropsychological tests requires prolonged time, so validating an MHE count test that is easy, reproducible, and in less time is recommended. The S-ANT test is performed by asking the patient to nominate 20 animals in one minute. In the reference score for the non-Mexican population, the test is negative; if it is less than 15 animals, it is positive and suggests MHE. This study aimed to assess the validity of the S-ANT scale as a screening test in patients with cirrhosis without overt HD.

Material and Methods: We present a prospective, descriptive, and analytical study of patients with cirrhosis of different etiology, without manifest HE to those who underwent S-ANT, PHES, and Flicker test. to validate the S-ANT test, the area under the curve of the receiver operator characteristic (AUROC) curve was calculated. Its Sensitivity (S) and specificity (SE) were determined, and MHE was considered when PHES and Flicker were positive for MHE. Statistical analysis The number of animals that patients with and without MHE were compared with the student's t-test for independent groups. The Sensitivity and specificity were calculated with the AUROC cut-off point for the S-ANT score for MHE+.

Results: The mean S-ANT for MHE- was 19.35±5.4 and for MHE+ 14.7±5.6, p=0.024 AUROC was significant .760 (.577- .942, 95%CI); p=0.037 with an S=83% and SE=77% cutoff= 17.5 words.

Conclusions: In the Mexican population, S-ANT reliably discriminates against patients with cirrhosis without overt HE with cognitive impairment, confirmed by PHES and Flicker test.



<https://doi.org/10.1016/j.aohep.2023.101237>

P-51 SERUM MICRORNA EXPRESSION ACCORDING TO THE PRESENCE OF LIVER DISEASE AND SARS-CoV-2 INFECTION

Lucas Lima Da¹, Luciane Almeida Amado², Otacilio Da Cruz³, Wagner Luis Da Costa Nunes Pimentel², Vanessa Duarte¹, Claudia Alexandra Pontes⁴, Lia Laura¹, Vanessa Salet³, Barbara Vieira¹, Livia Melo¹